Uploaded November 2022 | Updated November 2026, 3 hours ago
Since the first biosimilar approval in 2015, biosimilars have saved $13.3 billion for our health care system and patients. Biosimilars were used in more than 364 million days of patient therapy. Importantly, biosimilars led to more than 150 million incremental days of therapy.
Learn more in AAM's 2022 #GRxBiosimsSavingsReport: bit.ly/3UnZc7G
Since the first biosimilar approval in 2015, biosimilars have saved $13.3 billion for our health care system and patients. Biosimilars were used in more than 364 million days of patient therapy. Importantly, biosimilars led to more than 150 million incremental days of therapy.
Learn more in AAM's 2022 #GRxBiosimsSavingsReport: bit.ly/3UnZc7G










